Q-omics provides the consensus-scored BTN2A1 profile across patient tissues and cancer cell-line models. BTN2A1 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in BLCA. Among the 18 cancer types available for tumor–normal comparison, BTN2A1 is differentially expressed in 13, with the highest sampling consensus in HNSC. Additionally, BTN2A1 RNA expression shows 20,602 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight BLCA, HNSC, and ACC as cancer lineages where BTN2A1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for BTN2A1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes BTN2A1 survival associations across molecular data types. BTN2A1 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (3) and mass-spec protein abundance (8). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible BTN2A1 RNA expression–survival associations across cancer types. High BTN2A1 expression shows unfavorable associations in COAD, KICH and ESCA, but favorable associations in BLCA, KIRC and UCS. The BLCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .003). Together, the overview and detailed table identify BLCA as the clearest survival context for BTN2A1 RNA expression.
This table summarizes BTN2A1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 4. The strongest signals are observed in HNSC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for BTN2A1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. BTN2A1 shows lower tumor expression in KICH and LUSC and higher tumor expression in HNSC, KIRC, LIHC and STAD. The HNSC box plot shows higher BTN2A1 RNA expression in tumor versus normal tissue (log2 FC = +0.850, t-test p < 0.001).
This table shows molecular features associated with BTN2A1 in patient tissues and cancer cell lines. In patient samples, BTN2A1 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, BTN2A1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LARGE_INTESTINE, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and BLOOD_Leukemia.
